Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Bionic Pancreas Feasibility Trial Testing the Bionic Pancreas With ZP4207

X
Trial Profile

The Bionic Pancreas Feasibility Trial Testing the Bionic Pancreas With ZP4207

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasiglucagon (Primary) ; Glucagon; Insulin lispro
  • Indications Hypoglycaemia
  • Focus Adverse reactions
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 07 Mar 2018 According to Zealand Pharma media release, results from this trial were presented at the Conference on Advanced Technologies & Treatments for Diabetes (2018).
    • 15 Feb 2018 According to Zealand Pharma media release, results (n=12) from this trial will be presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (2018).
    • 22 Jun 2017 Results published in a Zealand Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top